Absci to Report Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results on March 24, 2026

Rhea-AI Summary

Absci (Nasdaq: ABSI) will report business updates and fourth-quarter and full-year 2025 financial and operating results after market close on March 24, 2026.

A webcast and live audio conference call will begin at 4:30 p.m. ET (1:30 p.m. PT), with the live stream and archived replay available via the company’s investor relations site at investors.absci.com.

Key Figures

Shelf registration size: $400,000,000 ATM capacity: $100,000,000 Q3 2025 partner revenue: $0.378 million +5 more

8 metrics

Shelf registration size $400,000,000 Total securities under Form S-3 shelf filed 2025-08-12

ATM capacity $100,000,000 Common stock under sales agreement with TD Securities

Q3 2025 partner revenue $0.378 million Quarter ended September 30, 2025

Q3 2025 net loss $28.7 million Quarter ended September 30, 2025

Cash & securities $152.5 million Balance as of September 30, 2025

Shares outstanding 150,371,531 As of October 31, 2025

HEADLINE trial size Up to 227 participants Phase 1/2a ABS-201 trial design

52-week range $2.01–$5.41 Pre-announcement trading range

Market Reality Check

Price: $2.65 Vol: Volume 2,293,523 vs 20-da...

normal vol

$2.65 Last Close

Volume Volume 2,293,523 vs 20-day average 3,054,183 ahead of the earnings update announcement. normal

Technical Shares at $2.65, trading below the 200-day MA of $3.10 and 51.02% under the 52-week high.

Peers on Argus

Peers showed mixed moves: gains in CGEM (3.02%) and ATXS (0.8%), declines in INB...

Peers showed mixed moves: gains in CGEM (3.02%) and ATXS (0.8%), declines in INBX (-4.07%) and LXRX (-0.66%), and a small rise in YMAB (0.23%), suggesting no clear sector-wide driver tied to this scheduling news.

Common Catalyst Some peers, such as CGEM, also reported investor conference participation, indicating a broader period of corporate communications rather than a unified price trend.

Historical Context

5 past events · Latest: Feb 17 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 17	Investor conferences	Positive	+4.3%	Planned participation in several March 2026 investor conferences and webcasts.
Dec 16	Major conference	Positive	+4.7%	Presentation and webcast at the 44th Annual J.P. Morgan Healthcare Conference.
Dec 11	Clinical data update	Positive	-3.3%	New human ex vivo data on ABS-201 suggesting potential reversal of follicle miniaturization.
Dec 10	Patient advocacy deal	Positive	+12.8%	Partnership with Landon Donovan to elevate patient voice in hair-loss research for ABS-201.
Dec 04	Trial initiation	Positive	+11.7%	First participants dosed in Phase 1/2a HEADLINE trial of AI-designed antibody ABS-201.

Pattern Detected

Positive corporate updates, including clinical and conference news, have more often aligned with positive price reactions, with one notable divergence on clinical data.

Recent Company History

Over recent months, Absci has highlighted multiple milestones. In December 2025, it began dosing participants in the Phase 1/2a HEADLINE trial for ABS-201 and shared strong investor interest around hair-loss data and a patient-focused partnership, which saw several double-digit percentage moves. Conference participation in December 2025 and February 2026 also coincided with moderate gains. Against this backdrop, the newly announced March 24, 2026 earnings date continues a pattern of regular updates on both clinical progress and investor outreach.

Regulatory & Risk Context

Active S-3 Shelf · $400,000,000

Shelf Active

Active S-3 Shelf Registration 2025-08-12

$400,000,000 registered capacity

An active Form S-3 shelf filed on August 12, 2025 allows Absci to offer up to $400,000,000 in various securities, including up to $100,000,000 of common stock via a sales agreement with TD Securities (USA) LLC, providing flexibility for future capital raises.

Market Pulse Summary

This announcement schedules Absci’s fourth quarter and full year 2025 results for March 24, 2026, co...

Analysis

This announcement schedules Absci’s fourth quarter and full year 2025 results for March 24, 2026, continuing a cadence of regular updates alongside prior conference and clinical news. Ahead of this date, the stock traded 51.02% below its 52-week high and below its $3.10 200-day moving average. Key context includes a Form S-3 shelf for up to $400,000,000 in securities and recent clinical progress with ABS-201, making upcoming revenue trends, cash usage, and pipeline timelines important items to watch.

Key Terms

generative ai, webcast

2 terms

generative ai technical

"advancing breakthrough therapeutics designed with generative AI, today announced the company"

Generative AI is a type of computer technology that can create new content, like text, images, or music, on its own. It’s important because it can produce realistic and useful material quickly, which could change how we create art, write stories, or even develop new products. Think of it as a smart robot that can invent and produce things almost like a human.

webcast technical

"Absci management will webcast a corresponding conference call beginning at 4:30 p.m."

A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.

AI-generated analysis. Not financial advice.

VANCOUVER, Wash. and NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will report business updates and financial and operating results for the fourth quarter and full year 2025 after market close on Tuesday, March 24, 2026.

Absci management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss its business developments, financial and operating results, and outlook.

Live audio of the webcast will be available on the company’s investor relations website at: investors.absci.com. The webcast will be archived and available for replay after the event.

About Absci

Absci is advancing the future of drug discovery with generative design to create better biologics for patients, faster. Our Integrated Drug Creation™ platform combines cutting-edge AI models with a synthetic biology data engine, enabling the rapid design of innovative therapeutics that address challenging therapeutic targets. Absci’s approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Each cycle refines our data and strengthens our models, facilitating rapid innovation and enhancing the precision of our therapeutic designs. Alongside collaborations with top pharmaceutical, biotech, tech, and academic leaders, Absci is advancing its own pipeline of AI designed therapeutics including ABS-201™, a groundbreaking innovation in hair regrowth with the potential to redefine treatment possibilities for androgenetic alopecia, commonly known as male and female pattern hair-loss. ABS-201 is also being investigated as a potential “best-in-class” therapeutic for endometriosis, a condition with significant unmet medical need and market potential. Absci is headquartered in Vancouver, WA, with AI Research Labs in New York City and Serbia, and an Innovation Center in Switzerland. Learn more at www.absci.com or follow us on LinkedIn (@absci), X (@Abscibio) and YouTube.

Absci® standard character mark, ABS-201™, and Integrated Drug Creation™ are trademarks and registered trademarks of Absci Corporation.

Investor Contact
Alexander D.H. Khan
Corporate Vice President, Head of Investor Relations
investors@absci.com

Media Contact
press@absci.com

FAQ

When will Absci (ABSI) report Q4 and full-year 2025 results?

Absci will report Q4 and full-year 2025 results after market close on March 24, 2026. According to the company, management will release business updates and financial and operating results and discuss outlook during the webcasted conference call that same day.

What time is the Absci (ABSI) earnings conference call on March 24, 2026?

The Absci conference call begins at 4:30 p.m. Eastern Time on March 24, 2026. According to the company, the call will follow the results release and include management discussion of business developments, financial results, and outlook.

Where can investors access the Absci (ABSI) webcast and replay?

Investors can access the live webcast and archived replay on Absci’s investor relations website at investors.absci.com. According to the company, live audio will stream during the call and the webcast will be archived for later replay.

Will Absci (ABSI) discuss business developments during the March 24, 2026 call?

Yes. Absci management will discuss business developments during the March 24, 2026 call and webcast. According to the company, the session will cover recent operating progress, financial results for Q4 and full-year 2025, and the company’s outlook.

How can shareholders prepare to follow Absci’s (ABSI) March 24, 2026 results release?

Shareholders should plan to join the webcast at 4:30 p.m. ET and review the company’s published materials after the release. According to the company, the webcast will be available live and archived on the investor relations website for later review.